BACKGROUND: Monocyte chemoattractant proteins (MCPs) play an important role in mediating inflammatory processes. Hypertension (HTN) is associated with inflammation as well as impaired cardiac microcirculatory function and structure, but the contribution of MCPs to these alterations remained unclear. This study tested the hypothesis that MCPs regulate cardiac microvascular function and structure in experimental HTN. METHODS AND RESULTS: Pigs (n=6 per group) were studied after 10 weeks of normal, renovascular HTN, or renovascular HTN+ bindarit (MCPs inhibitor, 50 mg/kg/d PO). Left ventricular (LV) function, myocardial microvascular permeability, and fractional vascular volume were assessed by fast computed tomography before and after adenosine infusion (400 microg/kg/min). Myocardial fibrosis, inflammation, and microvascular remodeling were determined ex vivo. Hypertension was not altered by bindarit, but LV hypertrophy and diastolic function were improved. In response to adenosine, myocardial microvascular permeability increased in HTN (from 0.0083+/-0.0009 to 0.0103+/-0.0011 AU, P=0.038 versus baseline) and fractional vascular volume decreased, whereas both remained unchanged in normal and HTN+bindarit pigs. HTN upregulated endothelin-1 expression, myocardial inflammation, and microvascular wall thickening, which were inhibited by bindarit. CONCLUSIONS: MCPs partly mediate myocardial inflammation, fibrosis, vascular remodeling, and impaired vascular integrity induced by hypertension. Inhibition of MCPs could potentially be a therapeutic target in hypertensive cardiomyopathy.
BACKGROUND: Monocyte chemoattractant proteins (MCPs) play an important role in mediating inflammatory processes. Hypertension (HTN) is associated with inflammation as well as impaired cardiac microcirculatory function and structure, but the contribution of MCPs to these alterations remained unclear. This study tested the hypothesis that MCPs regulate cardiac microvascular function and structure in experimental HTN. METHODS AND RESULTS:Pigs (n=6 per group) were studied after 10 weeks of normal, renovascular HTN, or renovascular HTN+ bindarit (MCPs inhibitor, 50 mg/kg/d PO). Left ventricular (LV) function, myocardial microvascular permeability, and fractional vascular volume were assessed by fast computed tomography before and after adenosine infusion (400 microg/kg/min). Myocardial fibrosis, inflammation, and microvascular remodeling were determined ex vivo. Hypertension was not altered by bindarit, but LV hypertrophy and diastolic function were improved. In response to adenosine, myocardial microvascular permeability increased in HTN (from 0.0083+/-0.0009 to 0.0103+/-0.0011 AU, P=0.038 versus baseline) and fractional vascular volume decreased, whereas both remained unchanged in normal and HTN+bindaritpigs. HTN upregulated endothelin-1 expression, myocardial inflammation, and microvascular wall thickening, which were inhibited by bindarit. CONCLUSIONS: MCPs partly mediate myocardial inflammation, fibrosis, vascular remodeling, and impaired vascular integrity induced by hypertension. Inhibition of MCPs could potentially be a therapeutic target in hypertensive cardiomyopathy.
Authors: L O Lerman; K A Nath; M Rodriguez-Porcel; J D Krier; R S Schwartz; C Napoli; J C Romero Journal: Hypertension Date: 2001-02 Impact factor: 10.190
Authors: K F Hilgers; A Hartner; M Porst; M Mai; M Wittmann; C Hugo; D Ganten; H Geiger; R Veelken; J F Mann Journal: Kidney Int Date: 2000-12 Impact factor: 10.612
Authors: S Möhlenkamp; L O Lerman; A Lerman; T R Behrenbeck; Z S Katusić; P F Sheedy; E L Ritman Journal: Circulation Date: 2000-11-07 Impact factor: 29.690
Authors: Xiang-Yang Zhu; Elena Daghini; Alejandro R Chade; Claudio Napoli; Erik L Ritman; Amir Lerman; Lilach O Lerman Journal: J Am Soc Nephrol Date: 2007-03-07 Impact factor: 10.121
Authors: Xin Zhang; Zi-Lun Li; John A Crane; Kyra L Jordan; Aditya S Pawar; Stephen C Textor; Amir Lerman; Lilach O Lerman Journal: Hypertension Date: 2014-04-21 Impact factor: 10.190
Authors: Ahmed Saad; Sandra M S Herrmann; Alfonso Eirin; Christopher M Ferguson; James F Glockner; Haraldur Bjarnason; Michael A McKusick; Sanjay Misra; Lilach O Lerman; Stephen C Textor Journal: Circ Cardiovasc Interv Date: 2017-09 Impact factor: 6.546
Authors: Victor H Urbieta-Caceres; Xiang-Yang Zhu; Kyra L Jordan; Hui Tang; Kyle Textor; Amir Lerman; Lilach O Lerman Journal: Atherosclerosis Date: 2011-10-12 Impact factor: 5.162
Authors: Victor H Urbieta-Caceres; Xiang-Yang Zhu; Matthew E Gibson; Frederic D Favreau; Kyra Jordan; Amir Lerman; Lilach O Lerman Journal: Am J Hypertens Date: 2011-01-13 Impact factor: 2.689
Authors: Lei Zhang; Xiang-Yang Zhu; Yu Zhao; Alfonso Eirin; Lei Liu; Christopher M Ferguson; Hui Tang; Amir Lerman; Lilach O Lerman Journal: Basic Res Cardiol Date: 2020-01-14 Impact factor: 17.165
Authors: Marcos L Aranda; Diego Guerrieri; Gonzalo Piñero; María F González Fleitas; Florencia Altschuler; Hernán H Dieguez; María I Keller Sarmiento; Mónica S Chianelli; Pablo H Sande; Damián Dorfman; Ruth E Rosenstein Journal: Mol Neurobiol Date: 2019-05-01 Impact factor: 5.590
Authors: Franziska J Klein; Stephen Bell; K Elisabeth Runte; Robert Lobel; Takamuru Ashikaga; Lilach O Lerman; Martin M LeWinter; Markus Meyer Journal: Am J Physiol Heart Circ Physiol Date: 2016-09-02 Impact factor: 4.733
Authors: Victor Hugo Urbieta Caceres; Jing Lin; Xiang-Yang Zhu; Frederic D Favreau; Matthew E Gibson; John A Crane; Amir Lerman; Lilach O Lerman Journal: Am J Physiol Heart Circ Physiol Date: 2010-12-03 Impact factor: 4.733
Authors: Alfonso Eirin; Barbara J Williams; Behzad Ebrahimi; Xin Zhang; John A Crane; Amir Lerman; Stephen C Textor; Lilach O Lerman Journal: J Hypertens Date: 2014-01 Impact factor: 4.844